See how researchers are using vivoVerse technology in their labs.
Dr. Parker’s lab members are using the vivoVerse vivoChip platform to immobilize age-synchronized adult animals in the device. Gilles was able to visualize up to 9 days adult C. elegans expressing fluorescent markers and interested to use the platform for long-term imaging experiments.
Claudia Maios and Gilles Tossing Alex Parker Lab University of Montreal
Product used: vivoChip
“The vivoCube and vivoChip system has revolutionized my imaging days. It is easy to set up, user-friendly, and fast.”
Lotti Brose Pierce-Shimomura Lab The University of Texas at Austin
Product used: vivoCube + vivoChip
“Their system is very easy to set up and use, the worms are robustly oriented, and the chip is suitable for high-resolution imaging.”
Steven Ban Saul Kato Lab UCSF
Product used: vivoChip
“vivoChip is an intelligent system—easy to use, very fast, and capable of beautiful wide-field and spinning-disc images.”
Claudia Maios and Gilles Tossing Alex Parker Lab University of Montreal
Product used: vivoChip
“vivoChip is an intelligent system—easy to use, very fast, and capable of beautiful wide-field and spinning-disc images.”
Claudia Maios and Gilles Tossing Alex Parker Lab University of Montreal
Product used: vivoChip
“We were excited to start using vivoCube, with hands-on support from the vivoVerse team to get us started.”
Joseph Liang Catharine Rankin Lab University of British Columbia
Product used: vivoCube
“We were excited to start using vivoCube, with hands-on support from the vivoVerse team to get us started.”
Joseph Liang Catharine Rankin Lab University of British Columbia
Product used: vivoCube
“We were excited to start using vivoCube, with hands-on support from the vivoVerse team to get us started.”
Joseph Liang Catharine Rankin Lab University of British Columbia
Product used: vivoCube
“The L4–YA chip was extremely effective for anesthetic-free live imaging while keeping animals in good condition for recovery.”
Nikhil Mishra Barbara Conradt Lab LMU Munich
Product used: vivoChip L4–YA
vivoChip enabled repeated, high-resolution 3D confocal imaging of lysosomal membrane permeabilization in the same animals over four hours.
Cliff J. Luke
Washington University School of Medicine in St. Louis
Researchers used vivoChip to score HSN neurodegeneration and investigate the interaction between APP and APOE4 in a C. elegans model.
Pierce-Shimomura Lab
The University of Texas at Austin
Talk with our team about your imaging workflow, research goals, and experimental needs.
Dr. Sudip Mondal has a Ph.D. in Physics and several years of postdoctoral research experience in neuroscience and microfluidics-based screening tools. He has developed several technologies that have translated to the market. One of his recent works at The University of Texas at Austin involved a high-throughput screening platform with C. elegans model systems, which is commercialized by vivoVerse. As a Director of Science, Sudip is responsible for developing new technologies and innovative assays to increase the vivoVerse product & service portfolio.
Evan Hegarty, co-founder, received his M.S. in Mechanical Engineering at The University of Texas at Austin while developing the technology and IP that lead to the launch of Newormics, LLC, now vivoVerse. As the Director of Manufacturing and Product development, and Principal Investigator of NIH SBIR grants at vivoVerse, Evan is responsible for development of all chip and system designs, creating production schedules, optimizing production methods, managing team members, identifying customer needs, developing future products, and reinforcing GLP and GMP.
A professor with dual appointments in Mechanical Engineering and Biomedical Engineering at The University of Texas at Austin, Dr Ben-Yakar’s research focuses on the creation of imaging technologies and novel laser surgery with high precision. Educated at Stanford and the Technion in Israel, with post-doctoral study at Harvard, and using her NIH Director’s Transformative Research Award, Dr Ben-Yakar began the research that has culminated in the launch of vivoVerse (formerly Newormics)
